Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 62

1.

Nf1 mutation expands an EGFR-dependent peripheral nerve progenitor that confers neurofibroma tumorigenic potential.

Williams JP, Wu J, Johansson G, Rizvi TA, Miller SC, Geiger H, Malik P, Li W, Mukouyama YS, Cancelas JA, Ratner N.

Cell Stem Cell. 2008 Dec 4;3(6):658-69. doi: 10.1016/j.stem.2008.10.003.

2.

Hematopoietic stem cell function and survival depend on c-Myc and N-Myc activity.

Laurenti E, Varnum-Finney B, Wilson A, Ferrero I, Blanco-Bose WE, Ehninger A, Knoepfler PS, Cheng PF, MacDonald HR, Eisenman RN, Bernstein ID, Trumpp A.

Cell Stem Cell. 2008 Dec 4;3(6):611-24. doi: 10.1016/j.stem.2008.09.005.

3.

c-Myc is required for maintenance of glioma cancer stem cells.

Wang J, Wang H, Li Z, Wu Q, Lathia JD, McLendon RE, Hjelmeland AB, Rich JN.

PLoS One. 2008;3(11):e3769. doi: 10.1371/journal.pone.0003769. Epub 2008 Nov 20.

4.

Virotherapy as an approach against cancer stem cells.

Ribacka C, Hemminki A.

Curr Gene Ther. 2008 Apr;8(2):88-96. Review.

PMID:
18393830
5.

CD133: molecule of the moment.

Mizrak D, Brittan M, Alison M.

J Pathol. 2008 Jan;214(1):3-9. Review.

PMID:
18067118
6.

Neuroblastoma cells isolated from bone marrow metastases contain a naturally enriched tumor-initiating cell.

Hansford LM, McKee AE, Zhang L, George RE, Gerstle JT, Thorner PS, Smith KM, Look AT, Yeger H, Miller FD, Irwin MS, Thiele CJ, Kaplan DR.

Cancer Res. 2007 Dec 1;67(23):11234-43.

7.

Cancer stem cells as mediators of treatment resistance in brain tumors: status and controversies.

Sakariassen PØ, Immervoll H, Chekenya M.

Neoplasia. 2007 Nov;9(11):882-92. Review.

8.

Tumor growth need not be driven by rare cancer stem cells.

Kelly PN, Dakic A, Adams JM, Nutt SL, Strasser A.

Science. 2007 Jul 20;317(5836):337.

9.

In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state.

Wernig M, Meissner A, Foreman R, Brambrink T, Ku M, Hochedlinger K, Bernstein BE, Jaenisch R.

Nature. 2007 Jul 19;448(7151):318-24. Epub 2007 Jun 6.

PMID:
17554336
10.

Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized primary nonmalignant and malignant tumor-derived human prostate epithelial cell lines and in prostate cancer specimens.

Miki J, Furusato B, Li H, Gu Y, Takahashi H, Egawa S, Sesterhenn IA, McLeod DG, Srivastava S, Rhim JS.

Cancer Res. 2007 Apr 1;67(7):3153-61.

11.

Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential.

Monzani E, Facchetti F, Galmozzi E, Corsini E, Benetti A, Cavazzin C, Gritti A, Piccinini A, Porro D, Santinami M, Invernici G, Parati E, Alessandri G, La Porta CA.

Eur J Cancer. 2007 Mar;43(5):935-46. Epub 2007 Feb 22.

PMID:
17320377
12.

Treatment of implantable NF2 schwannoma tumor models with oncolytic herpes simplex virus G47Delta.

Prabhakar S, Messerli SM, Stemmer-Rachamimov AO, Liu TC, Rabkin S, Martuza R, Breakefield XO.

Cancer Gene Ther. 2007 May;14(5):460-7. Epub 2007 Feb 16.

PMID:
17304235
13.

Oncolytic HSV and erlotinib inhibit tumor growth and angiogenesis in a novel malignant peripheral nerve sheath tumor xenograft model.

Mahller YY, Vaikunth SS, Currier MA, Miller SJ, Ripberger MC, Hsu YH, Mehrian-Shai R, Collins MH, Crombleholme TM, Ratner N, Cripe TP.

Mol Ther. 2007 Feb;15(2):279-86.

PMID:
17235305
14.

A perivascular niche for brain tumor stem cells.

Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, Hamner B, Oh EY, Gaber MW, Finklestein D, Allen M, Frank A, Bayazitov IT, Zakharenko SS, Gajjar A, Davidoff A, Gilbertson RJ.

Cancer Cell. 2007 Jan;11(1):69-82.

15.
16.

Stem cells in mammary development and carcinogenesis: implications for prevention and treatment.

Dontu G, Liu S, Wicha MS.

Stem Cell Rev. 2005;1(3):207-13. Review.

PMID:
17142857
17.

Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma.

Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR, Lu L, Irvin D, Black KL, Yu JS.

Mol Cancer. 2006 Dec 2;5:67.

18.

Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells.

Suetsugu A, Nagaki M, Aoki H, Motohashi T, Kunisada T, Moriwaki H.

Biochem Biophys Res Commun. 2006 Dec 29;351(4):820-4. Epub 2006 Nov 2.

PMID:
17097610
19.

SP analysis may be used to identify cancer stem cell populations.

Hadnagy A, Gaboury L, Beaulieu R, Balicki D.

Exp Cell Res. 2006 Nov 15;312(19):3701-10. Epub 2006 Sep 9. Review.

PMID:
17046749
20.

Defining the actual sensitivity and specificity of the neurosphere assay in stem cell biology.

Singec I, Knoth R, Meyer RP, Maciaczyk J, Volk B, Nikkhah G, Frotscher M, Snyder EY.

Nat Methods. 2006 Oct;3(10):801-6.

PMID:
16990812
Items per page

Supplemental Content

Write to the Help Desk